Corporate Governance29 Oct 2026, 05:21 pm
Senores Pharma: Monitoring Agency Report for IPO Proceeds Q3 FY27
AI Summary
Senores Pharmaceuticals Limited has submitted its Monitoring Agency Report for the quarter ended September 30, 2026, concerning the utilization of its Initial Public Offer (IPO) proceeds. The report, issued by CARE Ratings Limited, confirms no deviation from the IPO's stated objects. The utilization of the Rs. 500 crore IPO funds was reviewed by the Audit Committee and approved by the Board of Directors on October 29, 2026. The company had previously obtained shareholder approval for revised objects and timelines via postal ballot on August 04, 2026. The report will be available on the company's website.
Key Highlights
- Monitoring Agency Report for IPO proceeds submitted for Q3 FY27.
- No deviation observed in the utilization of IPO funds.
- Report reviewed by Audit Committee and Board of Directors.
- Rs. 500 crore IPO proceeds utilization confirmed.
- Shareholder approval obtained for revised objects and timelines.
Price Impact
More from SENORES